Skip to main content
RHHBY
OTC Life Sciences

Roche's Giredestrant Combo Nearly Doubles PFS in Advanced Breast Cancer; FDA Accepts NDA

Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$51.88
Mkt Cap
$334.884B
52W Low
$40.05
52W High
$60.85
52W Position info
30% above low
Off High info
15% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

RHHBY sits 30% above its 52-week low of $40.05.

Summary

Genentech's giredestrant plus everolimus significantly improved progression-free survival in ER-positive advanced breast cancer, with median PFS of 10.0 vs 5.5 months in ESR1-mutated patients (HR=0.38) and 8.8 vs 5.5 months in the ITT population (HR=0.56). The FDA accepted the NDA for this combination with a PDUFA date of December 18, 2026, and also accepted a Priority Review NDA for adjuvant giredestrant with a PDUFA date of November 30, 2026. This is the first positive Phase III readout for giredestrant and positions it as a potential new standard in post-CDK4/6 inhibitor breast cancer. The data were published in NEJM, adding credibility. Watch for FDA decisions in late 2026.

At the time of this announcement, RHHBY was trading at $51.88 on OTC in the Life Sciences sector, with a market capitalization of approximately $334.9B. The 52-week trading range was $40.05 to $60.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

RHHBY - Latest Insights

RHHBY
Nov 16, 2026, 1:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $60.30
Real-time Price: $60.95 info
Change: +$0.650 (+1%) info
Market Cap: $384.639B info
RHHBY
Oct 25, 2026, 11:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $61.17
Real-time Price: $60.95 info
Change: -$0.220 (-0.36%) info
Market Cap: $384.639B info
RHHBY
Oct 23, 2026, 1:30 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $60.19
Real-time Price: $60.95 info
Change: +$0.760 (+1%) info
Market Cap: $384.639B info
RHHBY
Oct 22, 2026, 12:50 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $59.48
Real-time Price: $60.95 info
Change: +$1.47 (+2%) info
Market Cap: $384.639B info
RHHBY
Oct 16, 2026, 1:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $56.78
Real-time Price: $60.95 info
Change: +$4.17 (+7%) info
Market Cap: $384.639B info